New eye drops could bring relief to millions with chronic dry eye
NCT ID NCT06903611
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether CAM-101 eye drops can reduce eye discomfort and corneal damage in people with moderate to severe dry eye. About 475 adults will receive either CAM-101 or a placebo for 9 weeks, then all participants can switch to CAM-101 for a year. The study aims to see if this treatment improves symptoms and eye surface health better than a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CAM-101 (fibrinogen-depleted human platelet lysate eye drops)
- What this could lead to
- If successful, this could offer a new treatment option for people with moderate to severe dry eye, potentially reducing eye discomfort and improving corneal health.
- What could go wrong
- This is an early-stage Phase 3 trial, so results are not yet known. The treatment may not work better than placebo, and there could be side effects like eye irritation or infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY EYE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can insulin eye drops quench dry eyes?
- Can a new eye drop soothe severe dry eye?
- New imaging tools put to the test for measuring dry eye treatment effects
- Could your own blood cure dry eye? plasma drops put to the test
- Could a special screen light reduce tired eyes and dryness?
- Nasal spray could make contact lenses more comfortable